Retatrutide Dosage Protocol (30 mg Vial)

Straightforward 12-week and 24-week planning for a 30 mg vial at 10 mg/mL.

• Retatrutide vials (30 mg each):
  • Phase 2, 12 weeks: Minimum 2 vials (56 mg required).
  • Phase 2, 24 weeks: Minimum 7 vials (200 mg required).
  • Phase 3, 12 weeks: Minimum 2 vials (48 mg required).
  • Phase 3, 24 weeks: Minimum 6 vials (180 mg required).
• U-100 insulin syringes (1 mL capacity):
  • Phase 2, 12 weeks: 12 new syringes.
  • Phase 2, 24 weeks: 36 new syringes.
  • Phase 3, 12 weeks: 12 new syringes.
  • Phase 3, 24 weeks: 32 new syringes.
• Bacteriostatic water (10 mL bottles):
  • Phase 2, 12 weeks: 1 bottle by volume (6 mL required).
  • Phase 2, 24 weeks: 3 bottles by volume (21 mL required).
  • Phase 3, 12 weeks: 1 bottle by volume (6 mL required).
  • Phase 3, 24 weeks: 2 bottles by volume (18 mL required).
• Alcohol swabs:
  • Phase 2, 12 weeks: 24 swabs minimum; 1 box of 100 covers the calculation.
  • Phase 2, 24 weeks: 60 swabs minimum; 1 box of 100 covers the calculation.
  • Phase 3, 12 weeks: 24 swabs minimum; 1 box of 100 covers the calculation.
  • Phase 3, 24 weeks: 56 swabs minimum; 1 box of 100 covers the calculation.

Sharps disposal: One appropriately sized container for used syringes.

Stability planning: Vial and diluent totals are minimum arithmetic quantities. Follow the exact product documentation for sterility, storage, handling loss, and discard timing.

Retatrutide 30 mg

Research-labeled vial

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

Practice preparing this vial with the verified strength and final volume from this protocol.

• Reconstitute: Add 3 mL of bacteriostatic water to produce 10 mg/mL.
• Research frequency: Once weekly by subcutaneous administration in the cited human trials.^[1][3][5]
• Weekly research range: The cited programs evaluated target amounts through 12 mg weekly.^[1][2][3]
• Easy measuring: 1 U-100 unit = 0.01 mL = 100 mcg.
• Vial size: The 30 mg label is total nominal vial content, not a weekly amount.
• Vial coverage: At the 2 mg research stage, one vial supplies 15 full weekly amounts. At the 12 mg research stage, one vial supplies 2 full weekly amounts with 6 mg remaining. These are mass calculations, not vial storage or discard periods.

The 30 mg protocol separates clinical-trial schedules from strength-specific vial arithmetic.

• Route and frequency: Once-weekly subcutaneous administration was used in the cited phase 2 and phase 3 trials.^[1][2][3][5]
• Studied targets: The obesity phase 2 program evaluated 1 mg, 4 mg, 8 mg, and 12 mg groups. Phase 3 programs evaluated 4 mg, 9 mg, and 12 mg targets.^[1][2][3]
• 30 mg vial concentration: 30 mg divided by 3 mL equals 10 mg/mL.
• U-100 conversion: 1 unit equals 0.01 mL or 100 mcg at this concentration.
• Evidence boundary: Trial schedules describe the investigated products and populations. They are not individualized dosing instructions.^[1][3][5][6]

Phase 2 and phase 3 used related but distinct Retatrutide dose-escalation designs.

• Phase 2 lower-start 12 mg arm: 2 mg, 4 mg, 8 mg, and then 12 mg in four-week stages.^[1][10]
• Phase 3 12 mg target: 2 mg, 4 mg, 6 mg, 9 mg, and then 12 mg in four-week stages.^[2][3]
• Other target groups: The programs included lower assigned targets rather than escalating every participant to 12 mg.^[1][2][3][5]
• Measurement: The primary chart keeps weekly peptide mass, U-100 units, mL, and frequency together.
• Strength consistency: The same research amount has the same peptide mass across Retatrutide vial sizes. Only concentration and required volume change.

The 30 mg vial provides different numbers of complete administrations at each research amount.

• 2 mg: 20 units or 0.20 mL, providing 15 complete administrations per 30 mg vial.
• 4 mg: 40 units or 0.40 mL, providing 7 complete administrations with 2 mg remaining.
• 6 mg: 60 units or 0.60 mL, providing 5 complete administrations.
• 9 mg: 90 units or 0.90 mL, providing 3 complete administrations with 3 mg remaining.
• 12 mg: 120 units or 1.20 mL, providing 2 complete administrations with 6 mg remaining. This volume exceeds one 1 mL U-100 syringe. Avoid unnecessary agitation and repeated freeze-thaw cycles because peptide stability is formulation-dependent.^[16]

A 30 mg Retatrutide vial reconstituted with 3 mL has a concentration of 10 mg/mL. The conversion is linear: each 0.01 mL U-100 unit contains 0.1 mg, or 100 mcg.

• A 2 mg research amount equals 0.20 mL or 20 U-100 units. One 30 mg vial contains 15 complete 2 mg amounts.
• A 4 mg amount equals 0.40 mL or 40 units. One vial contains 7 complete amounts with 2 mg remaining.
• A 6 mg amount equals 0.60 mL or 60 units. One vial contains 5 complete amounts.
• An 8 mg amount equals 0.80 mL or 80 units. One vial contains 3 complete amounts with 6 mg remaining.
• A 9 mg amount equals 0.90 mL or 90 units. One vial contains 3 complete amounts with 3 mg remaining.
• A 12 mg amount equals 1.20 mL or 120 units. One vial contains 2 complete amounts with 6 mg remaining. Because 120 units exceeds one 1 mL U-100 syringe, the supply calculation counts two syringes for that administration. Vial-yield figures are arithmetic, not storage or discard periods.

Retatrutide dosing in the cited studies was organized around assigned target groups and gradual escalation. The trial design determines the research schedule. The 30 mg vial label does not determine the weekly amount.

• The phase 2 obesity trial randomized participants to placebo or target groups of 1 mg, 4 mg, 8 mg, or 12 mg once weekly. Higher target groups used different starting and escalation approaches, including a lower 2 mg start that improved gastrointestinal tolerability compared with a 4 mg start.^[1][10]
• The phase 2 type 2 diabetes trial also evaluated several assigned Retatrutide doses and an active comparator. Its population, endpoints, and schedule context differ from the obesity trial.^[5][12]
• The TRIUMPH phase 3 program used once-weekly subcutaneous administration with assigned target doses and planned four-week escalation stages.^[2]
• TRANSCEND-T2D-1 evaluated 4 mg, 9 mg, and 12 mg target doses in adults with type 2 diabetes whose glycemic control was inadequate with diet and exercise.^[3]
• The clinical-trial registry identifies the tested protocol and population. It does not validate a separately manufactured 30 mg research vial or a self-directed schedule.^[6]

Retatrutide is an investigational single molecule designed to activate three metabolic hormone receptors: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon.

• GIP and GLP-1 receptor activity contributes to glucose-dependent insulin signaling, appetite regulation, and nutrient-response pathways.
• Glucagon receptor activity adds a distinct energy-expenditure and hepatic-signaling component to the research profile.
• Preclinical and translational work describes the balance of activity across the three receptors and the compound's extended pharmacokinetic profile.^[4]
• Reviews of multi-receptor agonists explain why triple agonism is being investigated for obesity and metabolic disease. Receptor activity alone does not establish a safe dose for an individual.^[7][8]

Clinical findings must be interpreted by trial, target dose, population, follow-up period, and analysis method. Results from one group should not be transferred to a different schedule or vial formulation.

• In the 48-week phase 2 obesity trial, mean body-weight change was dose-related, with the largest average reduction reported in the 12 mg target group.^[1]
• The phase 2 type 2 diabetes trial reported changes in glycated hemoglobin and body weight across the evaluated Retatrutide groups.^[5]
• TRANSCEND-T2D-1 reported phase 3 glycemic and body-weight outcomes at 40 weeks in adults with type 2 diabetes.^[3]
• Cardiometabolic measurements were assessed as secondary or exploratory outcomes and require population-specific interpretation.^[1][3][5][9]
• A phase 2a substudy evaluated liver-fat change in participants with metabolic dysfunction-associated steatotic liver disease. Those findings do not convert a 30 mg vial into a liver-treatment protocol.^[11]

Safety findings apply to the investigated products, monitored participants, and controlled escalation plans. Trial evidence, vial conversions, and informal schedules are different evidence categories.

• Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation were among the most frequently reported adverse events.^{[1][3][5][12]}
• A 2 mg starting amount improved gastrointestinal tolerability compared with a 4 mg start in the phase 2 obesity study.^[1]
• Dose-dependent heart-rate increases were observed in phase 2 and declined after peaking during follow-up.^[1]
• Trial design papers and registries describe assigned targets, eligibility criteria, comparators, and monitoring that are not reproduced by a vial calculation.^[2][6]
• Mechanistic and review literature can explain triple-receptor agonism but cannot independently validate a clinical dose.^[4][7][8]
• Cardiovascular and hepatic discussions remain outcome-specific and should not be converted into broad treatment claims.^[9][11]

These answers clarify how to read the 30 mg vial chart and handle research measurements without turning the information into individualized medical advice.^[13][14][15]

• What concentration results from adding 3 mL to a 30 mg vial? The concentration is 10 mg/mL. On a U-100 syringe, 1 unit equals 0.01 mL or 100 mcg.
• Does a 30 mg vial change the Retatrutide dose used in a trial? No. Vial strength changes concentration, volume, unit markings, vial yield, and supply calculations. It does not change the assigned research amount.
• How often was Retatrutide administered in the cited trials? The cited phase 2 and phase 3 studies used once-weekly subcutaneous administration.^[1][2][3][5]
• Did every participant escalate to 12 mg? No. Trials included multiple assigned target groups, and participants followed the protocol for their randomized group.^[1][2][3][5]
• How should research administration be documented? Follow the governing protocol, use a new sterile syringe, clean the vial stopper and selected site, rotate sites, record the mass, units, mL, date, and site, and place used sharps into an appropriate container.^[13][14][15]
• How many 12 mg amounts are in a 30 mg vial? Two complete 12 mg amounts fit within 30 mg, leaving 6 mg. That is mass arithmetic only and does not extend a documented storage or discard period. Avoid repeated freeze-thaw exposure because formulation stability may be affected.^[16]

This page summarizes published human research schedules and the corresponding arithmetic for a 30 mg vial. It does not establish an approved product, a recommended dose, or individualized medical advice.

• 1
  New England Journal of Medicine (2023): Triple-Hormone-Receptor Agonist Retatrutide for Obesity: randomized phase 2 trial

  View Source
• 2
  Diabetes, Obesity and Metabolism (2026): TRIUMPH Phase 3 trial design, target doses, and escalation

  View Source
• 3
  The Lancet (2026): TRANSCEND-T2D-1 randomized phase 3 retatrutide trial

  View Source
• 4
  Cell Metabolism (2022): Discovery and translational pharmacology of LY3437943

  View Source
• 5
  The Lancet (2023): Retatrutide for type 2 diabetes: randomized phase 2 trial

  View Source
• 6
  ClinicalTrials.gov: Phase 2 retatrutide obesity study NCT04881760

  View Source
• 7
  Current Obesity Reports (2025): Triple agonism-based therapies for obesity

  View Source
• 8
  Nature Reviews Endocrinology (2024): Multi-receptor agonists for metabolic disease

  View Source
• 9
  Diabetes Care (2024): Incretin-based therapies and cardiovascular considerations

  View Source
• 10
  New England Journal of Medicine (2023): Supplementary material for the phase 2 obesity trial

  View Source
• 11
  Nature Medicine (2024): Retatrutide for metabolic dysfunction-associated steatotic liver disease: randomized phase 2a trial

  View Source
• 12
  The Lancet (2023): Supplementary data for the phase 2 diabetes trial

  View Source
• 13
  CDC: Subcutaneous administration guidance

  View Source
• 14
  Johns Hopkins Arthritis Center: How to give a subcutaneous injection

  View Source
• 15
  NCBI Bookshelf: Best practices for injections and related procedures

  View Source
• 16
  Journal of Pharmaceutical Sciences (2018): Stability considerations during freeze-thaw cycles

  View Source

Compare the other Retatrutide vial sizes and practical measurement guides.